ANIX
Neutral signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Anixa Biosciences, Inc.
- Nom
- Anixa Biosciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $97.0M
- Employés
- 4
- PDG
- Amit Kumar
- Site web
- https://www.anixa.com
- Marché
- ABOSACTUAGENENTXHURAINO
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 77 036 titres (~210 766,84 $ US)
- Insiders
- Titterton Lewis H jrKUMAR AMITBaskies Arnold M
- Total bought
-
$210,767
Avg buy (VWAP, 90d window) $2.76 vs last close $2.99 (+8.3%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-23
- Liquidity
- Illiquid $715,807/day · 20d vol
- Last synced
-
2026-10-26 22:35:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-22 | KUMAR AMIT | Buy · P | 8,000 | $2.72 | $21,760 | Form 4 |
| 2026-09-30 | Catelani Michael | Buy · P | 5,500 | $2.84 | $15,620 | Form 4 |
| 2026-09-24 | Baskies Arnold M | Buy · P | 5,000 | $2.76 | $13,800 | Form 4 |
| 2026-09-24 | KUMAR AMIT | Buy · P | 7,000 | $2.78 | $19,460 | Form 4 |
| 2026-09-23 | Titterton Lewis H jr | Buy · P | 49,036 | $2.69 | $131,907 | Form 4 |
| 2026-09-10 | KUMAR AMIT | Buy · P | 3,000 | $2.75 | $8,250 | Form 4 |
| 2026-09-10 | Titterton Lewis H jr | Buy · P | 10,000 | $2.73 | $27,300 | Form 4 |
| 2026-07-31 | KUMAR AMIT | Buy · P | 5,000 | $3.47 | $17,350 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ANIX presents a compelling event-driven signal — a meaningful insider cluster buy combined with a positive CAR-T ovarian cancer trial readout — but this is sharply offset by severe fundamental weakness: zero revenue…
The first sentence of the analysis written for ANIX on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 8.08 · operating margin 0.0%
Suggested stop 2.77, nearest stored support minus 0.5 ATR(7.3% under the last close). Reward/risk to the next stored resistance is 0.55. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to date Patients in fifth cohort received 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., Oct. 26, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
- 2026-10-13 Anixa Biosciences'' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa''s CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference.
- 2026-10-05 Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.
- 2026-10-01 Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
- 2026-09-28 Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) Director Arnold Baskies purchased 5,000 shares of the firm''s stock in a transaction on Thursday, September 24th. The shares were acquired at an average price of $2.76 per share, with a total value of $13,800.00. Following the purchase, the director directly owned 140,572 shares in the company,
- 2026-09-28 Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) CEO Amit Kumar acquired 7,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, September 24th. The shares were bought at an average price of $2.78 per share, with a total value of $19,460.00. Following the transaction, the chief executive officer directly owned 672,000
- 2026-09-21 Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 Composition of matter patent secures exclusive protection for Anixa''s breast cancer vaccine in Australia through 2040, expanding the Company''s growing global IP estate Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., Sept. 21, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa''s breast cancer vaccine technology, exclusively licensed from Cleveland Clinic.
- 2026-09-16 Anixa Biosciences Appoints UPenn''s Dr. Carmen Guerra to Cancer Business Advisory Board SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D.
- 2026-09-09 Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET.
- 2026-09-03 Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 Presentation to highlight Anixa''s clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq''s San Francisco headquarters.
Market snapshot
Financial ratios
| Metric | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 23.3% | 0.0% | 24.8% | |
| Ebit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2565.6% | |
| Ebitda Margin | 0.0% | 0.0% | -4706.7% | 0.0% | -2553.9% | |
| Operating Profit Margin | 0.0% | 0.0% | -5243.3% | 0.0% | -2565.6% | |
| Pretax Profit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2564.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2564.0% | |
| Net Profit Margin | 0.0% | 0.0% | -4671.9% | 0.0% | -2528.6% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -4671.9% | 0.0% | -2530.1% | |
| Current Ratio | 8.077 | 8.545 | 12.503 | 14.826 | 28.349 | |
| Quick Ratio | 8.077 | 8.545 | 12.503 | 14.848 | 28.349 | |
| Solvency Ratio | -5.113 | -4.631 | -4.540 | -6.127 | -8.645 | |
| Cash Ratio | 0.632 | 0.508 | 0.451 | 6.068 | 22.936 | |
| Price To Earnings Ratio | -12.147 | -8.974 | -9.875 | -12.444 | -11.311 | |
| Price To Earnings Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Forward Price To Earnings Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Price To Earnings Diluted Ratio | -12.147 | -8.974 | -9.875 | -12.444 | -11.311 | |
| Price To Earnings Diluted Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Price To Book Ratio | 8.841 | 5.583 | 4.023 | 5.856 | 4.105 | |
| Price To Sales Ratio | 0.000 | 0.000 | 466.175 | 0.000 | 284.114 | |
| Price To Free Cash Flow Ratio | -18.686 | -15.221 | -15.767 | -26.201 | -29.459 | |
| Price To Operating Cash Flow Ratio | -18.686 | -15.221 | -15.767 | -26.201 | -29.459 | |
| Debt To Assets Ratio | 0.013 | 0.011 | 0.007 | 0.007 | 0.007 | |
| Debt To Equity Ratio | 0.013 | 0.012 | 0.007 | 0.008 | 0.007 | |
| Debt To Capital Ratio | 0.013 | 0.011 | 0.007 | 0.008 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.061 | 1.080 | 1.049 | 1.047 | 1.023 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.008 | 0.000 | 0.024 | |
| Operating Cash Flow Ratio | -3.647 | -2.934 | -3.062 | -3.187 | -3.888 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -29.567 | 0.000 | -9.645 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -268.098 | 0.000 | 0.000 | -132.010 | -40,609.118 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -133.413 | -40,794.075 | |
| Short Term Operating Cash Flow Coverage Ratio | -174.951 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -35.162 | -31.616 | -35.480 | -29.376 | -19.066 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.099 | -8.736 | -9.830 | -11.505 | -8.917 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-9.6% |
| Ebit Margin | 0.0% | 0.0% | ▲1458.8% |
| Ebitda Margin | 0.0% | 0.0% | ▲1452.1% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1561.8% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲1458.5% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲1458.5% |
| Net Profit Margin | 0.0% | 0.0% | ▲1440.1% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲1440.4% |
| Current Ratio | 8.077 | ▼-0.468 | ▼-6.383 |
| Quick Ratio | 8.077 | ▼-0.468 | ▼-6.388 |
| Solvency Ratio | -5.113 | ▼-0.482 | ▲0.698 |
| Cash Ratio | 0.632 | ▲0.124 | ▼-5.487 |
| Price To Earnings Ratio | -12.147 | ▼-3.173 | ▼-1.197 |
| Price To Earnings Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Forward Price To Earnings Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Price To Earnings Diluted Ratio | -12.147 | ▼-3.173 | ▼-1.197 |
| Price To Earnings Diluted Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Price To Book Ratio | 8.841 | ▲3.258 | ▲3.159 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-150.058 |
| Price To Free Cash Flow Ratio | -18.686 | ▼-3.466 | ▲2.381 |
| Price To Operating Cash Flow Ratio | -18.686 | ▼-3.466 | ▲2.381 |
| Debt To Assets Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Debt To Equity Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Debt To Capital Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.061 | ▼-0.019 | ▲0.009 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.006 |
| Operating Cash Flow Ratio | -3.647 | ▼-0.713 | ▼-0.303 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲7.842 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | -268.098 | ▼-268.098 | ▲7933.748 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲8185.498 |
| Short Term Operating Cash Flow Coverage Ratio | -174.951 | ▼-174.951 | ▼-139.961 |
| Operating Cash Flow Coverage Ratio | -35.162 | ▼-3.545 | ▼-5.022 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.099 | ▼-3.364 | ▼-1.882 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $134.0M | $111.6M | $97.9M | $170.1M | $145.5M | |
| Enterprise value | $133.0M | $110.6M | $97.2M | $158.0M | $116.6M | |
| EV / Sales | 0.00x | 0.00x | 462.65x | 0.00x | 227.73x | |
| EV / Op. cash flow | -18.54x | -15.08x | -15.65x | -24.33x | -23.61x | |
| EV / Free cash flow | -18.54x | -15.08x | -15.65x | -24.33x | -23.61x | |
| EV / EBITDA | -12.10x | -8.74x | -9.83x | -11.51x | -8.92x | |
| Net debt / EBITDA | 0.10x | 0.08x | 0.07x | 0.88x | 2.21x | |
| Current ratio | 8.08x | 8.54x | 12.50x | 14.83x | 28.35x | |
| Income quality | 0.65x | 0.58x | 0.62x | 0.47x | 0.38x | |
| Graham net-net | $0 | $1 | $1 | $1 | $1 | |
| Tax burden | 99.1% | 98.9% | 98.8% | 98.7% | 98.6% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 99.9% | |
| Working capital | $13.9M | $18.9M | $23.3M | $28.2M | $34.7M | |
| Invested capital | $14.1M | $19.1M | $23.5M | $28.4M | $35.0M | |
| Return on assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | |
| Operating ROA | -62.1% | -58.7% | -39.4% | -41.6% | -57.5% | |
| Return on tangible assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | |
| Return on equity | -72.1% | -62.8% | -40.3% | -46.8% | -36.5% | |
| Return on invested capital | -82.7% | -72.3% | -46.8% | -48.8% | -37.5% | |
| Return on capital employed | -82.9% | -72.4% | -46.9% | -48.9% | -37.5% | |
| Earnings yield | -8.2% | -11.2% | -10.0% | -8.0% | -8.9% | |
| Free cash flow yield | -5.4% | -6.6% | -6.3% | -3.8% | -3.4% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 2995.7% | 0.0% | 1381.5% | |
| R&D / Sales | 0.0% | 0.0% | 2271.0% | 0.0% | 1208.9% | |
| Stock comp / Sales | 0.0% | 0.0% | 2105.7% | 0.0% | 1465.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 469d | 0d | 0d | |
| Days payables outstanding | 1673d | 0d | 467d | 0d | 129d | |
| Operating cycle | 0d | 0d | 469d | 0d | 0d | |
| Cash conversion cycle | -1673d | 0d | 2d | 0d | -129d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years